At the news
? BULLISHIMPACT 6/10 8-K filed Jul 29, 2026 at 11:38 ET
AbCellera announced a collaboration with Vertex Pharmaceuticals to discover and develop multispecific T-cell engagers (TCEs) for autoimmune diseases. AbCellera receives $28 million in total upfront payments and is eligible for preclinical, development, regulatory, and commercial milestone payments plus tiered royalties. Vertex funds all R&D costs and has commercialization rights. This partnership validates AbCellera's TCE platform and provides non-dilutive capital, but no financial guidance or revenue impact was disclosed.
- AbCellera announced a collaboration with Vertex Pharmaceuticals (Nasdaq: VRTX) to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions.
- AbCellera will receive $28 million in total upfront payments.
- AbCellera is eligible to receive preclinical, development, regulatory, and commercial milestone payments, along with tiered royalties on net sales.
- Vertex will fund all research and development costs and will have the right to develop and commercialize therapeutic multispecific antibodies resulting from the collaboration.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access